Dyslipidemia in Breast Cancer patients
El Hini, S., Saad El Din, A., Mohamed, M., Ahmed, A. (2020). Dyslipidemia in Breast Cancer patients. EKB Journal Management System, 31(4), 192-196. doi: 10.21608/mjmr.2022.217927
Sahar H. El Hini; Ahmed M. Saad El Din; Marwa , I. Mohamed; Asmma K. Ahmed. "Dyslipidemia in Breast Cancer patients". EKB Journal Management System, 31, 4, 2020, 192-196. doi: 10.21608/mjmr.2022.217927
El Hini, S., Saad El Din, A., Mohamed, M., Ahmed, A. (2020). 'Dyslipidemia in Breast Cancer patients', EKB Journal Management System, 31(4), pp. 192-196. doi: 10.21608/mjmr.2022.217927
El Hini, S., Saad El Din, A., Mohamed, M., Ahmed, A. Dyslipidemia in Breast Cancer patients. EKB Journal Management System, 2020; 31(4): 192-196. doi: 10.21608/mjmr.2022.217927

Dyslipidemia in Breast Cancer patients

Minia Journal of Medical Research
Volume 31, Issue 4, October 2020, Page 192-196  XML PDF (115.88 K)
Document Type: Original Article
DOI: 10.21608/mjmr.2022.217927
View on SCiNiTO View on SCiNiTO
Authors
Sahar H. El Hini1; Ahmed M. Saad El Din1; Marwa , I. Mohamed2; Asmma K. Ahmed2
1Department of Internal Medicine, Diabetes and Endocrinology unit, Minia School of Medicine, Minia University
2Department of Internal Medicine, Diabetes and Endocrinology unit, Minia School of Medicine, Minia University.
Abstract
Background: Breast cancer (BC) is the most prevalent cancer and primary cause of cancerrelated mortality in women. The identification of risk factors can improve prevention of 
cancer[1]
. Research on breast cancer cells have demonstrated an important role for cholesterol 
and its transporters in breast cancer development. Instead of cholesterol, the cholesterol 
metabolite 27-hydroxycholesterol induces the proliferation of estrogen receptor-positive 
breast cancer cells and facilitates metastasis[2]. Oxidative modification of the lipoproteins and 
HDL glycation activate different inflammation-related pathways, thereby enhancing cell 
proliferation and migration and inhibiting apoptosis[3]
. Aim of the work: The study’s primary 
aim was to investigate the LDL, HDL and TG serum levels in patients with BC and in 
comparison with control subjects. In addition to evaluate different BC risk factors. Patients 
and Methods: The study estimated LDL, HDL and TG serum levels in 70 patients with BC 
and 50 healthy subject. Results: patient with breast cancer had significantly higher level of 
serum LDL with a mean (133.39±23.76) compared to control subjects (119.26±11.01) as p 
value (<0.001), HDL level was significantly low in breast cancer patients compared to 
control with a mean (52.74±5.9) in breast cancer patients compared to (55.88±5.34) in control 
subjects as p value (0.003) and Triglycerides level was significantly high in breast cancer 
patients compared to control with a mean (141.79±17.74) in breast cancer patients compared 
to (132.04±11.95) in control subjects as p value (0.001). Conclusion: Serum HDL level is 
significantly lower in breast cancer patients compared to control. While serum LDL and
triglycerides are significantly higher.

Keywords
Breast cancer; low-density; high density lipoproteins
Supplementary Files
Statistics
Article View: 80
PDF Download: 72